 Brian Day
Concepts (546)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antioxidants | 43 | 2024 | 530 | 6.320 |
Why?
| | Glutathione | 28 | 2017 | 293 | 5.470 |
Why?
| | Metalloporphyrins | 26 | 2024 | 103 | 4.000 |
Why?
| | Oxidative Stress | 42 | 2024 | 1076 | 3.850 |
Why?
| | Thiocyanates | 6 | 2019 | 29 | 2.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2021 | 590 | 1.940 |
Why?
| | Lung | 23 | 2023 | 3558 | 1.840 |
Why?
| | Reactive Oxygen Species | 21 | 2018 | 531 | 1.780 |
Why?
| | Mustard Gas | 7 | 2016 | 117 | 1.720 |
Why?
| | Chemical Warfare Agents | 4 | 2016 | 119 | 1.650 |
Why?
| | Particulate Matter | 4 | 2021 | 185 | 1.620 |
Why?
| | ATP-Binding Cassette Transporters | 5 | 2012 | 122 | 1.370 |
Why?
| | Smoking | 9 | 2015 | 1380 | 1.210 |
Why?
| | Immunity, Innate | 3 | 2019 | 720 | 1.050 |
Why?
| | Lung Injury | 4 | 2023 | 197 | 0.980 |
Why?
| | Antidotes | 3 | 2016 | 135 | 0.960 |
Why?
| | Lung Diseases | 4 | 2021 | 701 | 0.950 |
Why?
| | Mesalamine | 2 | 2017 | 8 | 0.930 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2012 | 287 | 0.930 |
Why?
| | Flavonoids | 3 | 2011 | 66 | 0.910 |
Why?
| | Animals | 67 | 2024 | 31694 | 0.910 |
Why?
| | Berylliosis | 4 | 2017 | 177 | 0.890 |
Why?
| | Inflammation | 11 | 2020 | 2477 | 0.890 |
Why?
| | Cystic Fibrosis | 4 | 2020 | 955 | 0.870 |
Why?
| | Mitochondria | 11 | 2015 | 747 | 0.860 |
Why?
| | Superoxide Dismutase | 12 | 2015 | 305 | 0.850 |
Why?
| | Pneumonia | 2 | 2020 | 567 | 0.840 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2023 | 1139 | 0.840 |
Why?
| | Molecular Mimicry | 3 | 2008 | 35 | 0.740 |
Why?
| | Acetylcysteine | 5 | 2016 | 141 | 0.710 |
Why?
| | Inhalation Exposure | 5 | 2016 | 97 | 0.710 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2020 | 22 | 0.710 |
Why?
| | Interleukin-33 | 1 | 2020 | 38 | 0.700 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 225 | 0.690 |
Why?
| | Epithelial Cells | 9 | 2022 | 950 | 0.690 |
Why?
| | Oxidation-Reduction | 14 | 2017 | 923 | 0.690 |
Why?
| | Thioredoxin-Disulfide Reductase | 3 | 2015 | 14 | 0.680 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 104 | 0.660 |
Why?
| | Prodrugs | 1 | 2019 | 42 | 0.660 |
Why?
| | Mice | 35 | 2021 | 14860 | 0.660 |
Why?
| | Chalcones | 5 | 2012 | 9 | 0.650 |
Why?
| | Neoplasm Proteins | 4 | 2014 | 384 | 0.650 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1477 | 0.610 |
Why?
| | Inflammation Mediators | 5 | 2018 | 477 | 0.610 |
Why?
| | Allergens | 1 | 2021 | 413 | 0.590 |
Why?
| | Beryllium | 3 | 2009 | 146 | 0.590 |
Why?
| | Electronic Nicotine Delivery Systems | 3 | 2023 | 71 | 0.570 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 191 | 0.570 |
Why?
| | Cell Line | 13 | 2020 | 2635 | 0.560 |
Why?
| | Deoxyguanosine | 3 | 2016 | 26 | 0.550 |
Why?
| | Wound Healing | 1 | 2019 | 258 | 0.550 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 4689 | 0.550 |
Why?
| | Organometallic Compounds | 2 | 2009 | 98 | 0.540 |
Why?
| | Manganese | 4 | 2024 | 55 | 0.540 |
Why?
| | Free Radical Scavengers | 6 | 2013 | 78 | 0.530 |
Why?
| | Catalase | 4 | 2013 | 118 | 0.530 |
Why?
| | Industrial Waste | 1 | 2015 | 5 | 0.520 |
Why?
| | War Exposure | 1 | 2015 | 10 | 0.520 |
Why?
| | Immunity, Cellular | 1 | 2017 | 248 | 0.510 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2004 | 82 | 0.500 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2016 | 58 | 0.500 |
Why?
| | Peroxidases | 1 | 2015 | 25 | 0.490 |
Why?
| | Respiratory Mucosa | 4 | 2011 | 251 | 0.480 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 299 | 0.480 |
Why?
| | Lymphocytes | 3 | 2017 | 330 | 0.480 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2013 | 71 | 0.470 |
Why?
| | Skin | 3 | 2014 | 655 | 0.460 |
Why?
| | Respiratory System | 1 | 2015 | 137 | 0.460 |
Why?
| | Rats, Sprague-Dawley | 14 | 2024 | 2218 | 0.450 |
Why?
| | Afghanistan | 4 | 2021 | 108 | 0.440 |
Why?
| | Cell Survival | 8 | 2014 | 1020 | 0.430 |
Why?
| | Cytokines | 7 | 2018 | 1840 | 0.420 |
Why?
| | Macrophages, Alveolar | 3 | 2011 | 347 | 0.420 |
Why?
| | Cell Proliferation | 6 | 2017 | 2186 | 0.420 |
Why?
| | Rats | 17 | 2024 | 4958 | 0.410 |
Why?
| | DNA, Mitochondrial | 4 | 2009 | 182 | 0.400 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2012 | 12 | 0.400 |
Why?
| | Macrophages | 6 | 2020 | 1261 | 0.400 |
Why?
| | Influenza A virus | 2 | 2023 | 90 | 0.400 |
Why?
| | Environmental Exposure | 1 | 2015 | 372 | 0.400 |
Why?
| | Chemokines, CC | 1 | 2012 | 28 | 0.400 |
Why?
| | DNA | 4 | 2016 | 1352 | 0.390 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 447 | 0.390 |
Why?
| | Pinocytosis | 1 | 2011 | 10 | 0.390 |
Why?
| | Humans | 53 | 2023 | 114623 | 0.390 |
Why?
| | Glutathione Peroxidase | 2 | 2008 | 41 | 0.390 |
Why?
| | Nerve Agents | 2 | 2024 | 4 | 0.390 |
Why?
| | Smoke | 3 | 2013 | 123 | 0.390 |
Why?
| | Extracellular Space | 2 | 2011 | 116 | 0.380 |
Why?
| | Chalcone | 1 | 2011 | 2 | 0.380 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2011 | 109 | 0.380 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2011 | 144 | 0.380 |
Why?
| | Doxorubicin | 2 | 2011 | 285 | 0.360 |
Why?
| | Adaptation, Physiological | 2 | 2011 | 483 | 0.360 |
Why?
| | Membrane Transport Proteins | 1 | 2012 | 138 | 0.360 |
Why?
| | Macrophage Activation | 1 | 2011 | 164 | 0.360 |
Why?
| | Virus Diseases | 2 | 2023 | 194 | 0.360 |
Why?
| | Lung Neoplasms | 4 | 2011 | 2177 | 0.340 |
Why?
| | Sulfasalazine | 1 | 2009 | 21 | 0.340 |
Why?
| | Chelating Agents | 1 | 2009 | 65 | 0.340 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 2710 | 0.330 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 21 | 0.330 |
Why?
| | Male | 36 | 2021 | 55554 | 0.330 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 77 | 0.320 |
Why?
| | Adenosine Triphosphate | 2 | 2015 | 430 | 0.320 |
Why?
| | Oxidants | 4 | 2019 | 112 | 0.320 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 184 | 0.310 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 32 | 0.310 |
Why?
| | Status Epilepticus | 3 | 2017 | 32 | 0.310 |
Why?
| | Mycoplasma pneumoniae | 1 | 2008 | 28 | 0.310 |
Why?
| | Apoptosis | 9 | 2015 | 2362 | 0.300 |
Why?
| | Lymphocyte Activation | 3 | 2009 | 1037 | 0.300 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2319 | 0.300 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2005 | 10 | 0.300 |
Why?
| | Mice, Inbred CFTR | 4 | 2012 | 5 | 0.300 |
Why?
| | Chlorine | 3 | 2015 | 62 | 0.300 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2011 | 470 | 0.290 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2011 | 913 | 0.290 |
Why?
| | Mitochondria, Liver | 2 | 2004 | 67 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2011 | 636 | 0.280 |
Why?
| | Influenza, Human | 2 | 2023 | 546 | 0.280 |
Why?
| | Peroxidase | 3 | 2020 | 163 | 0.270 |
Why?
| | Carrier Proteins | 1 | 2010 | 695 | 0.260 |
Why?
| | Cisplatin | 1 | 2007 | 262 | 0.260 |
Why?
| | Neoplasms | 3 | 2014 | 2097 | 0.260 |
Why?
| | Mice, Knockout | 10 | 2015 | 2565 | 0.250 |
Why?
| | Administration, Oral | 5 | 2021 | 728 | 0.250 |
Why?
| | Disease Models, Animal | 11 | 2021 | 3531 | 0.250 |
Why?
| | Epilepsy, Temporal Lobe | 2 | 2015 | 20 | 0.250 |
Why?
| | Hydrogen Peroxide | 5 | 2012 | 288 | 0.250 |
Why?
| | Microsomes, Liver | 1 | 2005 | 55 | 0.240 |
Why?
| | Chronic Disease | 6 | 2017 | 1578 | 0.240 |
Why?
| | Hippocampus | 4 | 2017 | 693 | 0.240 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 427 | 0.240 |
Why?
| | Monocytes | 2 | 2021 | 502 | 0.240 |
Why?
| | Pulmonary Fibrosis | 1 | 2008 | 323 | 0.240 |
Why?
| | Stavudine | 1 | 2004 | 8 | 0.240 |
Why?
| | Flavins | 1 | 2004 | 1 | 0.230 |
Why?
| | Nucleosides | 1 | 2004 | 25 | 0.230 |
Why?
| | Lipid Peroxidation | 7 | 2007 | 139 | 0.220 |
Why?
| | Pulmonary Edema | 1 | 2003 | 115 | 0.210 |
Why?
| | DNA Replication | 1 | 2004 | 202 | 0.210 |
Why?
| | Bronchoalveolar Lavage | 2 | 2021 | 84 | 0.210 |
Why?
| | Signal Transduction | 6 | 2020 | 4509 | 0.210 |
Why?
| | Anticonvulsants | 2 | 2017 | 179 | 0.210 |
Why?
| | Cells, Cultured | 8 | 2018 | 3881 | 0.210 |
Why?
| | Double-Blind Method | 2 | 2017 | 1660 | 0.200 |
Why?
| | Vaping | 1 | 2023 | 45 | 0.200 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 821 | 0.200 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 73 | 0.200 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 959 | 0.200 |
Why?
| | Electrochemistry | 1 | 2002 | 79 | 0.200 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 502 | 0.190 |
Why?
| | Substrate Specificity | 3 | 2013 | 352 | 0.190 |
Why?
| | Pulmonary Alveoli | 2 | 2020 | 373 | 0.190 |
Why?
| | Aging | 2 | 2010 | 1618 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2016 | 1842 | 0.190 |
Why?
| | Oxygen | 4 | 2015 | 854 | 0.190 |
Why?
| | Administration, Inhalation | 3 | 2015 | 641 | 0.180 |
Why?
| | Adenocarcinoma | 1 | 2007 | 795 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1879 | 0.180 |
Why?
| | Thiobarbituric Acid Reactive Substances | 4 | 2007 | 20 | 0.180 |
Why?
| | Brain | 3 | 2018 | 2371 | 0.180 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 28 | 0.180 |
Why?
| | Burkholderia | 1 | 2020 | 13 | 0.170 |
Why?
| | Middle Aged | 9 | 2018 | 26719 | 0.170 |
Why?
| | Cyanates | 1 | 2019 | 4 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2017 | 161 | 0.170 |
Why?
| | Selenium Compounds | 1 | 2019 | 21 | 0.170 |
Why?
| | Glutamate-Cysteine Ligase | 2 | 2017 | 14 | 0.170 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 284 | 0.170 |
Why?
| | Particle Size | 1 | 2020 | 317 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 385 | 0.160 |
Why?
| | MPTP Poisoning | 2 | 2017 | 4 | 0.160 |
Why?
| | Morbidity | 1 | 2020 | 280 | 0.160 |
Why?
| | Mice, Hairless | 3 | 2014 | 74 | 0.160 |
Why?
| | Female | 18 | 2018 | 59466 | 0.160 |
Why?
| | Drug Synergism | 3 | 2012 | 316 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 298 | 0.150 |
Why?
| | Isoflurophate | 1 | 2018 | 5 | 0.150 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 14 | 0.150 |
Why?
| | Interleukin-13 | 1 | 2018 | 122 | 0.150 |
Why?
| | Neutrophils | 3 | 2020 | 1176 | 0.150 |
Why?
| | Kinetics | 2 | 2013 | 1551 | 0.140 |
Why?
| | Dimercaprol | 1 | 2017 | 6 | 0.140 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 26 | 0.140 |
Why?
| | Catalysis | 3 | 2008 | 289 | 0.140 |
Why?
| | Auranofin | 2 | 2013 | 9 | 0.140 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 849 | 0.140 |
Why?
| | Reactive Nitrogen Species | 2 | 2018 | 21 | 0.130 |
Why?
| | Cornea | 2 | 2007 | 102 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2007 | 102 | 0.130 |
Why?
| | Sulfhydryl Compounds | 2 | 2017 | 177 | 0.130 |
Why?
| | Aged | 5 | 2018 | 19061 | 0.130 |
Why?
| | Age Factors | 2 | 2015 | 2894 | 0.130 |
Why?
| | Neurons | 3 | 2018 | 1279 | 0.130 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 37 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 493 | 0.120 |
Why?
| | Intracellular Space | 2 | 2012 | 68 | 0.120 |
Why?
| | Thiourea | 2 | 2013 | 39 | 0.120 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 89 | 0.120 |
Why?
| | Mice, Inbred BALB C | 4 | 2013 | 1143 | 0.120 |
Why?
| | Comet Assay | 1 | 2014 | 18 | 0.120 |
Why?
| | Drug Resistance, Multiple | 1 | 2014 | 19 | 0.120 |
Why?
| | Adult | 7 | 2016 | 30528 | 0.120 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 106 | 0.120 |
Why?
| | Response Elements | 2 | 2012 | 82 | 0.120 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 2006 | 44 | 0.110 |
Why?
| | DNA Damage | 4 | 2009 | 351 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2011 | 80 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 97 | 0.110 |
Why?
| | Glycolysis | 1 | 2015 | 226 | 0.110 |
Why?
| | Biomarkers | 5 | 2018 | 3408 | 0.110 |
Why?
| | Hypochlorous Acid | 1 | 2013 | 4 | 0.110 |
Why?
| | Selenocysteine | 1 | 2013 | 3 | 0.110 |
Why?
| | Pollen | 1 | 2013 | 24 | 0.110 |
Why?
| | Cytoprotection | 2 | 2013 | 51 | 0.110 |
Why?
| | Bronchioles | 1 | 2013 | 22 | 0.110 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2013 | 45 | 0.110 |
Why?
| | Thioredoxin Reductase 2 | 1 | 2012 | 2 | 0.110 |
Why?
| | NADPH Oxidases | 1 | 2013 | 120 | 0.110 |
Why?
| | Bacteria | 1 | 2019 | 725 | 0.100 |
Why?
| | MAP Kinase Signaling System | 2 | 2017 | 276 | 0.100 |
Why?
| | Microbial Viability | 1 | 2013 | 79 | 0.100 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2010 | 107 | 0.100 |
Why?
| | Antigens | 1 | 2014 | 318 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1629 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1016 | 0.100 |
Why?
| | Alveolar Epithelial Cells | 1 | 2013 | 93 | 0.100 |
Why?
| | Dopaminergic Neurons | 1 | 2012 | 43 | 0.100 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 262 | 0.100 |
Why?
| | Transcriptional Activation | 2 | 2011 | 337 | 0.100 |
Why?
| | Cysteine | 1 | 2013 | 171 | 0.100 |
Why?
| | Random Allocation | 4 | 2017 | 335 | 0.100 |
Why?
| | Extracellular Fluid | 1 | 2011 | 30 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 331 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 347 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2009 | 150 | 0.090 |
Why?
| | Blood-Brain Barrier | 3 | 2021 | 106 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2015 | 476 | 0.090 |
Why?
| | Phagocytosis | 2 | 2012 | 350 | 0.090 |
Why?
| | Copper | 2 | 2009 | 100 | 0.090 |
Why?
| | Fumarate Hydratase | 2 | 2011 | 2 | 0.090 |
Why?
| | Aconitate Hydratase | 2 | 2011 | 16 | 0.090 |
Why?
| | Nasal Cavity | 1 | 2011 | 47 | 0.090 |
Why?
| | Olfactory Mucosa | 1 | 2011 | 60 | 0.090 |
Why?
| | Myocardium | 3 | 2015 | 913 | 0.090 |
Why?
| | Asthma | 3 | 2013 | 2029 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 287 | 0.090 |
Why?
| | HIV Infections | 2 | 2004 | 2469 | 0.090 |
Why?
| | Dopamine | 2 | 2017 | 236 | 0.090 |
Why?
| | Irritants | 1 | 2010 | 41 | 0.090 |
Why?
| | Bronchi | 1 | 2012 | 231 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2014 | 665 | 0.090 |
Why?
| | Apoproteins | 1 | 2009 | 12 | 0.090 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 301 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 52 | 0.080 |
Why?
| | Dermatitis, Irritant | 1 | 2009 | 11 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 396 | 0.080 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 108 | 0.080 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2009 | 86 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2010 | 119 | 0.080 |
Why?
| | Paraquat | 2 | 2012 | 14 | 0.080 |
Why?
| | Biological Transport | 1 | 2010 | 373 | 0.080 |
Why?
| | Demography | 1 | 2009 | 260 | 0.080 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Amino Acids | 2 | 2010 | 448 | 0.080 |
Why?
| | Biocatalysis | 1 | 2008 | 58 | 0.080 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2008 | 30 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2003 | 1691 | 0.080 |
Why?
| | Body Fluids | 1 | 2008 | 58 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2009 | 138 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2009 | 719 | 0.080 |
Why?
| | Iron | 1 | 2009 | 233 | 0.080 |
Why?
| | Epilepsy | 1 | 2011 | 277 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2013 | 736 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 923 | 0.070 |
Why?
| | Time Factors | 2 | 2016 | 6112 | 0.070 |
Why?
| | Electron Transport Complex I | 1 | 2007 | 33 | 0.070 |
Why?
| | Antiviral Agents | 2 | 2023 | 645 | 0.070 |
Why?
| | Fibrosis | 1 | 2009 | 453 | 0.070 |
Why?
| | Neurofibromin 1 | 1 | 2007 | 22 | 0.070 |
Why?
| | Eye Proteins | 1 | 2007 | 70 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 740 | 0.070 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 26 | 0.070 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 25 | 0.070 |
Why?
| | Quality of Life | 1 | 2017 | 2353 | 0.070 |
Why?
| | Neurofibromatosis 1 | 1 | 2007 | 36 | 0.070 |
Why?
| | Intestinal Absorption | 1 | 2007 | 93 | 0.070 |
Why?
| | Dexamethasone | 2 | 2012 | 317 | 0.070 |
Why?
| | Pilocarpine | 2 | 2017 | 7 | 0.070 |
Why?
| | Cell Fractionation | 1 | 2006 | 51 | 0.070 |
Why?
| | HL-60 Cells | 1 | 2006 | 28 | 0.070 |
Why?
| | Saccharomyces cerevisiae | 1 | 2010 | 476 | 0.070 |
Why?
| | Mycoplasma Infections | 1 | 2006 | 13 | 0.070 |
Why?
| | Stromal Cells | 1 | 2006 | 96 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2009 | 1083 | 0.070 |
Why?
| | Leukemia, Myeloid | 1 | 2006 | 40 | 0.070 |
Why?
| | Lens, Crystalline | 1 | 2007 | 90 | 0.070 |
Why?
| | Longevity | 1 | 2007 | 137 | 0.060 |
Why?
| | Corpus Striatum | 1 | 2007 | 126 | 0.060 |
Why?
| | Radiation Injuries | 1 | 2007 | 128 | 0.060 |
Why?
| | Models, Biological | 2 | 2010 | 1620 | 0.060 |
Why?
| | Drosophila melanogaster | 1 | 2007 | 191 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B1 | 1 | 2005 | 1 | 0.060 |
Why?
| | Young Adult | 2 | 2023 | 10455 | 0.060 |
Why?
| | Caspase 8 | 1 | 2005 | 43 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
| | Xenobiotics | 1 | 2005 | 24 | 0.060 |
Why?
| | Cations | 1 | 2005 | 78 | 0.060 |
Why?
| | Aldehydes | 3 | 2012 | 138 | 0.060 |
Why?
| | Cataract | 1 | 2007 | 185 | 0.060 |
Why?
| | Nitric Oxide Synthase | 2 | 2003 | 209 | 0.060 |
Why?
| | Insulin | 1 | 2014 | 2076 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 108 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2007 | 255 | 0.060 |
Why?
| | Oxidoreductases | 1 | 2005 | 92 | 0.060 |
Why?
| | Hypertension | 1 | 2012 | 1056 | 0.060 |
Why?
| | Ferritins | 1 | 2004 | 52 | 0.060 |
Why?
| | Liver Diseases | 1 | 2007 | 255 | 0.060 |
Why?
| | Caspases | 1 | 2005 | 245 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1141 | 0.060 |
Why?
| | Cell Respiration | 2 | 2015 | 74 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2018 | 535 | 0.060 |
Why?
| | Ischemia | 1 | 2007 | 362 | 0.060 |
Why?
| | Glyoxylates | 1 | 2003 | 9 | 0.060 |
Why?
| | Disease Progression | 1 | 2010 | 2380 | 0.050 |
Why?
| | Sulfonylurea Compounds | 1 | 2003 | 44 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 90 | 0.050 |
Why?
| | Half-Life | 2 | 2017 | 141 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2003 | 305 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 211 | 0.050 |
Why?
| | Parkinson Disease | 1 | 2007 | 345 | 0.050 |
Why?
| | Probability | 1 | 2003 | 289 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 385 | 0.050 |
Why?
| | Cardiomyopathies | 1 | 2006 | 298 | 0.050 |
Why?
| | Cell Death | 2 | 2015 | 322 | 0.050 |
Why?
| | Adolescent | 2 | 2023 | 17831 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 140 | 0.050 |
Why?
| | Nitric Acid | 1 | 2002 | 5 | 0.050 |
Why?
| | Endotoxemia | 1 | 2003 | 85 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 434 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 742 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 256 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1230 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 993 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 206 | 0.050 |
Why?
| | Iraq | 1 | 2021 | 81 | 0.050 |
Why?
| | Injury Severity Score | 1 | 2003 | 499 | 0.050 |
Why?
| | Epithelium | 1 | 2022 | 295 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 221 | 0.050 |
Why?
| | Mitochondria, Heart | 2 | 2015 | 73 | 0.050 |
Why?
| | Eosinophils | 1 | 2003 | 278 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2021 | 286 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 2507 | 0.040 |
Why?
| | Glutathione Disulfide | 2 | 2011 | 26 | 0.040 |
Why?
| | Blood Pressure | 2 | 2003 | 1538 | 0.040 |
Why?
| | Estrogens | 1 | 2002 | 312 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2017 | 785 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 931 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 4894 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2003 | 617 | 0.040 |
Why?
| | Liver | 1 | 2007 | 1634 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 561 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 921 | 0.040 |
Why?
| | Soman | 1 | 2018 | 1 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 20 | 0.040 |
Why?
| | Tyrosine | 2 | 2011 | 214 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1355 | 0.040 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 329 | 0.040 |
Why?
| | Toll-Like Receptor 2 | 1 | 2018 | 110 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1736 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 197 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2003 | 823 | 0.040 |
Why?
| | Gene Expression | 2 | 2013 | 1421 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2018 | 237 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1147 | 0.040 |
Why?
| | Mice, Inbred NOD | 2 | 2014 | 555 | 0.040 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2017 | 2 | 0.040 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 17 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2011 | 157 | 0.040 |
Why?
| | RNA | 1 | 2023 | 809 | 0.040 |
Why?
| | Transfection | 2 | 2012 | 866 | 0.040 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 99 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 119 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 908 | 0.030 |
Why?
| | Microglia | 1 | 2018 | 202 | 0.030 |
Why?
| | Nervous System | 1 | 2017 | 63 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2017 | 135 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2003 | 637 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3003 | 0.030 |
Why?
| | Drug Design | 1 | 2017 | 148 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 3328 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 843 | 0.030 |
Why?
| | Nootropic Agents | 1 | 2015 | 27 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 7 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 750 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 22 | 0.030 |
Why?
| | Kainic Acid | 1 | 2015 | 31 | 0.030 |
Why?
| | DNA Polymerase gamma | 2 | 2006 | 7 | 0.030 |
Why?
| | Military Personnel | 1 | 2021 | 523 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 119 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2008 | 9084 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 458 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 176 | 0.030 |
Why?
| | Betula | 1 | 2013 | 3 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2015 | 213 | 0.030 |
Why?
| | Oxidopamine | 1 | 2012 | 12 | 0.030 |
Why?
| | PPAR delta | 1 | 2012 | 6 | 0.030 |
Why?
| | Interferon-beta | 1 | 2013 | 79 | 0.030 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 28 | 0.030 |
Why?
| | Peroxiredoxins | 1 | 2012 | 23 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2012 | 44 | 0.030 |
Why?
| | Lentivirus | 1 | 2012 | 44 | 0.030 |
Why?
| | Mesencephalon | 1 | 2012 | 57 | 0.030 |
Why?
| | Papio | 2 | 2003 | 96 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2014 | 3244 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 1727 | 0.030 |
Why?
| | Motor Activity | 1 | 2017 | 640 | 0.030 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2012 | 13 | 0.030 |
Why?
| | Th2 Cells | 1 | 2013 | 154 | 0.030 |
Why?
| | NF-E2 Transcription Factor, p45 Subunit | 1 | 2012 | 3 | 0.030 |
Why?
| | Prospective Studies | 1 | 2003 | 6217 | 0.030 |
Why?
| | Emphysema | 1 | 2013 | 107 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 910 | 0.020 |
Why?
| | Coenzyme A | 1 | 2011 | 6 | 0.020 |
Why?
| | Holoenzymes | 1 | 2012 | 21 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 18 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 299 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 142 | 0.020 |
Why?
| | NAD | 1 | 2011 | 63 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 130 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2012 | 2552 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 758 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2012 | 257 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 449 | 0.020 |
Why?
| | Buthionine Sulfoximine | 1 | 2010 | 7 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 192 | 0.020 |
Why?
| | Dermatitis | 1 | 2010 | 17 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 285 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2010 | 49 | 0.020 |
Why?
| | Fibroblasts | 2 | 2006 | 837 | 0.020 |
Why?
| | Deoxyadenosines | 1 | 2009 | 7 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 591 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 304 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 362 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2009 | 26 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2009 | 30 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 778 | 0.020 |
Why?
| | Phenotype | 2 | 2007 | 2796 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 102 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2009 | 109 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 522 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 73 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1226 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2009 | 155 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2011 | 380 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2009 | 80 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2012 | 532 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 542 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 731 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2007 | 33 | 0.020 |
Why?
| | Nitrosation | 1 | 2007 | 8 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1369 | 0.020 |
Why?
| | Membrane Lipids | 1 | 2007 | 87 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2007 | 134 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 133 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 553 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2007 | 86 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 1889 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 27 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2007 | 241 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2007 | 227 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 215 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 141 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 303 | 0.020 |
Why?
| | Etoposide | 1 | 2006 | 148 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 45 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1313 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 638 | 0.020 |
Why?
| | Heart | 1 | 2009 | 612 | 0.020 |
Why?
| | Rabbits | 1 | 2006 | 733 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 718 | 0.020 |
Why?
| | Radioisotopes | 1 | 2004 | 28 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 363 | 0.010 |
Why?
| | fas Receptor | 1 | 2004 | 91 | 0.010 |
Why?
| | Phagocytes | 1 | 2004 | 90 | 0.010 |
Why?
| | Renal Blood Flow, Effective | 1 | 2003 | 2 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2004 | 188 | 0.010 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 12 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 75 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 353 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 73 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2002 | 136 | 0.010 |
Why?
| | DNA Polymerase beta | 1 | 2002 | 5 | 0.010 |
Why?
| | Permeability | 1 | 2003 | 149 | 0.010 |
Why?
| | Estrone | 1 | 2002 | 35 | 0.010 |
Why?
| | DNA Polymerase I | 1 | 2002 | 26 | 0.010 |
Why?
| | Linoleic Acid | 1 | 2002 | 37 | 0.010 |
Why?
| | Ions | 1 | 2002 | 59 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 248 | 0.010 |
Why?
| | S-Nitrosoglutathione | 1 | 2002 | 6 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2002 | 133 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2002 | 33 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2002 | 28 | 0.010 |
Why?
| | PC12 Cells | 1 | 2002 | 37 | 0.010 |
Why?
| | Free Radicals | 1 | 2002 | 99 | 0.010 |
Why?
| | Insulinoma | 1 | 2002 | 29 | 0.010 |
Why?
| | Electrons | 1 | 2002 | 71 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 334 | 0.010 |
Why?
| | Hyperoxia | 1 | 2003 | 99 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2002 | 77 | 0.010 |
Why?
| | Clone Cells | 1 | 2002 | 247 | 0.010 |
Why?
| | Occupational Exposure | 1 | 2004 | 255 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 195 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 278 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 137 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 135 | 0.010 |
Why?
| | Mice, SCID | 1 | 2002 | 314 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 712 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2006 | 1947 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 385 | 0.010 |
Why?
| | Models, Chemical | 1 | 2002 | 248 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 160 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 604 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 797 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 1982 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2002 | 588 | 0.010 |
Why?
| | Swine | 1 | 2002 | 700 | 0.010 |
Why?
| | Estradiol | 1 | 2002 | 455 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 920 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 386 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2002 | 633 | 0.010 |
Why?
| | Fatty Acids | 1 | 2002 | 381 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 1644 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2785 | 0.010 |
Why?
| | Fetus | 1 | 2003 | 699 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 615 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1188 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1104 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3344 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3039 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 5043 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 1862 | 0.010 |
Why?
|
|
Day's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|